THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial

for the THN102-202 Study Investigators

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


BACKGROUND: Excessive daytime sleepiness (EDS) is a frequent and disabling symptom of Parkinson's disease (PD) without approved treatment. THN102 is a novel combination drug of modafinil and low-dose flecainide.

OBJECTIVE: The aim of this study is to evaluate the safety and efficacy of THN102 in PD patients with EDS.

METHODS: The method involved a randomized, double-blind, placebo-controlled, crossover trial testing two doses of THN102 (200 mg/d modafinil with 2 mg/d [200/2] or 18 mg/d flecainide [200/18]) versus placebo; 75 patients were exposed to treatment. The primary endpoint was safety. The primary efficacy outcome was the change in Epworth Sleepiness Scale (ESS) score.

RESULTS: Both doses of THN102 were well tolerated. ESS significantly improved with THN102 200/2 (least square means vs. placebo [95% confidence interval, CI]: -1.4 [-2.49; -0.31], P = 0.012) but did not change significantly with the 200/18 dosage.

CONCLUSIONS: THN102 was well tolerated and showed a signal of efficacy at the 200/2 dose, supporting further development for the treatment of EDS in PD. © 2021 International Parkinson and Movement Disorder Society.

Original languageEnglish (US)
Pages (from-to)410-415
Number of pages6
JournalMovement Disorders
Issue number2
StatePublished - Feb 1 2022


  • Parkinson's disease; sleepiness; clinical trial; modafinil; flecainide
  • Disorders of Excessive Somnolence/etiology
  • Parkinson Disease/drug therapy
  • Double-Blind Method
  • Humans
  • Modafinil/adverse effects
  • Drug Combinations
  • Flecainide/adverse effects

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology


Dive into the research topics of 'THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial'. Together they form a unique fingerprint.

Cite this